Immix Biopharma Stock Total Debt
| IMMX Stock | USD 2.17 0.05 2.36% |
Immix Biopharma fundamentals help investors to digest information that contributes to Immix Biopharma's financial success or failures. It also enables traders to predict the movement of Immix Stock. The fundamental analysis module provides a way to measure Immix Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immix Biopharma stock.
Total Debt To Capitalization is likely to drop to 0 in 2024. Immix | Total Debt |
Immix Biopharma Company Total Debt Analysis
Immix Biopharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Immix Biopharma Total Debt | 50 K |
Most of Immix Biopharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immix Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immix Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Immix Biopharma is extremely important. It helps to project a fair market value of Immix Stock properly, considering its historical fundamentals such as Total Debt. Since Immix Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immix Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immix Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Immix Total Debt Historical Pattern
Today, most investors in Immix Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immix Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immix Biopharma total debt as a starting point in their analysis.
Immix Biopharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Immix Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Immix Biopharma has a Total Debt of 50 K. This is 100.0% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Immix Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immix Biopharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immix Biopharma could also be used in its relative valuation, which is a method of valuing Immix Biopharma by comparing valuation metrics of similar companies.Immix Biopharma is currently under evaluation in total debt category among related companies.
Immix Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Immix Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immix Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immix Biopharma's value.| Shares | Jump Financial, Llc | 2023-12-31 | 18.5 K | Blackrock Inc | 2023-12-31 | 17.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 16.2 K | Jane Street Group, Llc | 2023-12-31 | 14.9 K | Susquehanna International Group, Llp | 2023-12-31 | 14.4 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 11.9 K | Interocean Capital Group | 2023-12-31 | 11.9 K | Bank Of Montreal | 2023-12-31 | 10 K | Old National Bancorp | 2023-12-31 | 10 K | Vanguard Group Inc | 2023-12-31 | 160.4 K | Eam Investors, Llc | 2023-12-31 | 102.7 K |
Immix Fundamentals
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | 38.25 M | ||||
| Shares Outstanding | 26.4 M | ||||
| Shares Owned By Insiders | 45.91 % | ||||
| Shares Owned By Institutions | 8.56 % | ||||
| Number Of Shares Shorted | 349.89 K | ||||
| Price To Book | 4.47 X | ||||
| EBITDA | (16.13 M) | ||||
| Net Income | (15.43 M) | ||||
| Cash And Equivalents | 18.4 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 50 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 19.53 X | ||||
| Book Value Per Share | 0.82 X | ||||
| Cash Flow From Operations | (11.37 M) | ||||
| Short Ratio | 2.37 X | ||||
| Earnings Per Share | (0.89) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.049 | ||||
| Market Capitalization | 55.96 M | ||||
| Total Asset | 19.93 M | ||||
| Retained Earnings | (53.41 M) | ||||
| Working Capital | 16.07 M | ||||
| Net Asset | 19.93 M |
About Immix Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immix Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immix Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immix Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immix Biopharma Piotroski F Score and Immix Biopharma Altman Z Score analysis. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Immix Stock analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Immix Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. If investors know Immix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immix Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Return On Assets (0.58) | Return On Equity (1.06) |
The market value of Immix Biopharma is measured differently than its book value, which is the value of Immix that is recorded on the company's balance sheet. Investors also form their own opinion of Immix Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Immix Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immix Biopharma's market value can be influenced by many factors that don't directly affect Immix Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.